Precision oncology is becoming a practical strategy for building cancer-care capacity in Saudi Arabia through 2030. A major driver is the scale of need. Around 28,000 new cancer cases are reported in the Kingdom every year, with cases split roughly equally between women and men, according to World Health Organization figures cited by Middle East Health. Breast and colorectal cancer are the most frequently diagnosed, followed by thyroid cancer, Non-Hodgkin lymphoma, and leukaemia. The same source notes one forecast predicting cancer cases will double between 2020 and 2040, which sharpens the urgency to modernize care pathways and treatment decision-making.
Policy direction is also shaping how capacity is built. Middle East Health links the rise of precision oncology to Saudi Arabia’s Vision 2030 and its Health Sector Transformation Program, which calls for improving the quality of care and patients’ quality of life. The article argues that fragmented journeys do not serve patients well, and that a patient-first mindset matters as the Kingdom prepares for higher levels of cancer and other non-communicable diseases. In practice, this includes creating specialist disease teams and being willing to change long-standing processes so precision medicine can translate into more consistent, end-to-end oncology services.
Genomics And NGS: The Capacity Engine Behind Precision Care
Genomics and NGS are key building blocks for precision oncology because they support targeted therapy selection and more refined diagnosis. Ken Research values the Saudi Arabia Genomics in Cancer Care Market at approximately USD 320 million and notes that diagnostic testing is the leading type segment, supported by demand for early detection and adoption of genomic testing technologies. Hospitals are described as the dominant end-user segment, reflecting their role as primary cancer-care providers with infrastructure to implement genomic testing and treatment. Ken Research also reports the Saudi Arabia Clinical Oncology NGS Market is valued at approximately USD 9 million and ties growth to cancer incidence projected to rise from 28,113 cases in 2022 to 39,900 cases by 2030. A survey cited in that same NGS report indicates only 45% of oncologists were familiar with NGS applications, highlighting a utilization gap that directly affects how quickly capacity can translate into routine practice.
Market development is being reinforced by partnerships and a broader shift to precision tools. Grand View Research states the Saudi Arabia precision oncology market is anticipated to experience a lucrative CAGR during the forecast period and points to collaboration as an ecosystem accelerator. As an example, it cites a January 2025 Memorandum of Understanding between Boston Oncology Arabia and SPIMACO to produce advanced oral oncology treatments within the Kingdom, aimed at enhancing access to cutting-edge therapies and strengthening pharmaceutical infrastructure. In breast cancer care, Mobility Foresights describes how rising patient awareness, improved diagnostic imaging, and technological advancements in genomics are reshaping treatment practices, with precision oncology becoming central as clinicians incorporate molecular testing and biomarker profiling. It also highlights genomic profiling and technologies such as NGS, multi-gene panels, and liquid biopsies as tools improving treatment selection accuracy.
Regional context also signals where Saudi Arabia’s capabilities may need to align as precision medicine becomes more embedded in care delivery. Ken Research values the Middle East Precision Oncology Market at approximately USD 3.6 billion and describes therapeutics as the leading type segment, supported by demand for targeted therapies and immunotherapies, while diagnostics grows through advanced molecular testing and AI-driven imaging. It also identifies hospitals as the dominant end-user segment and notes that AI integration in diagnostics is expected to enhance accuracy and efficiency in cancer detection. For Saudi Arabia, the practical takeaway is that scaling precision oncology is not only about buying technology. It is also about strengthening hospital workflows, improving clinician familiarity with NGS, and building reliable local supply and manufacturing relationships so patient-first care can keep pace with rising demand through 2030.
How large is the cancer burden in Saudi Arabia today, and what trend is expected?
What do projections say about cancer incidence through 2030 in the Kingdom?
What is the current estimated value of Saudi Arabia’s genomics in cancer care market?
How familiar are oncologists with NGS applications in Saudi Arabia?
What is changing in the Saudi oncology market as precision medicine grows?
